01 / SIGNAL
Appetite signalling
GLP-1 receptor activation is reported in the literature to slow gastric emptying and modulate satiety signalling in the central nervous system.
Signature Line · Triple Agonist · Research Compound
Reta
Retatrutide.
A third-generation incretin research peptide. Retatrutide is reported in the literature to act on three receptors — GLP-1, GIP, and glucagon. Reference information only — not for human or animal consumption.
- Class
- Triple Agonist
- Pathway
- GLP-1 / GIP / Glucagon
- Route
- Subcutaneous
// 01About the compound
Retatrutide is a third-generation incretin research peptide. Where semaglutide acts on a single receptor and tirzepatide acts on two, retatrutide is reported in the published literature to act on three.
By co-activating GLP-1, GIP, and glucagon receptors, the compound is being examined in research for its parallel effects on appetite signalling, insulin-pathway sensitivity, and energy expenditure.
It is included in the Max Nutrition USA catalog as a current focus of metabolic research literature.
// 02Mechanism — what the literature describes
Four parallel mechanisms reported in the published research on triple-agonist incretin peptides.
02 / STABILIZE
Glucose pathway
Combined GIP and GLP-1 activation has been studied for effects on insulin-pathway sensitivity and post-prandial glucose dynamics.
03 / EXPENDITURE
Energy expenditure
Glucagon-receptor activation is examined in the literature for its association with resting energy expenditure and lipid-substrate utilisation.
04 / OUTCOMES
Body-composition research
Trial data published on triple-agonist incretin compounds has examined changes in body-composition endpoints relative to single- and dual-receptor agonists.
// 03Research focus areas
Triple-receptor pharmacology
Concurrent activation of GLP-1, GIP, and glucagon receptors is a primary subject of triple-agonist research.
Appetite-pathway signalling
Published research examines central and peripheral satiety-pathway effects.
Glucose-pathway endpoints
Studies examine insulin-pathway sensitivity and glycaemic-control endpoints.
Energy-expenditure endpoints
Glucagon-receptor activity is studied for its association with resting metabolic rate.
Long half-life pharmacokinetics
Published half-life of approximately six days is a focus of administration-frequency literature.
Body-composition research
Trial data examines lean-mass-preservation endpoints versus single- and dual-agonist comparators.
// 04Related research compounds
Tissue-repair research
BPC-157 + TB-500
Connective-tissue and systemic-repair pathway research.
View page → Endogenous GH researchCJC-1295 + Ipamorelin
Research on GHRH/GHRP-mediated growth-hormone pulse signalling.
View page → Mitochondrial researchMOTS-C 40mg
Mitochondrial-derived peptide research; cellular-energy pathway literature.
View page → Longevity researchNAD+ 500mg
Cellular-repair and longevity-pathway research compound.
View page →Research inquiries.
Direct line.
DM @max_nutritionusa for current Reta stock, pricing, CoA requests, and shipping. By contacting us you affirm you are a qualified researcher and will use any compound purchased strictly for laboratory research — not for human or animal consumption. We do not provide dosing or medical advice.
Disclaimer — Research Use Only
All products offered by Max Nutrition USA are sold strictly for in vitro laboratory research purposes only. Not for human or animal consumption. Not for diagnostic, therapeutic, or veterinary use.
These compounds have not been evaluated by the Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure, or prevent any disease. They are not approved drugs, dietary supplements, or cosmetics under the Federal Food, Drug, and Cosmetic Act.
All content on this site — including product names, mechanism descriptions, and references to scientific literature — is provided for educational and informational purposes only. Nothing on this site constitutes medical, pharmaceutical, or dosing advice. Always consult a qualified, licensed healthcare professional before considering any application involving these or any other compounds.
Buyer attestation. By submitting an inquiry or placing an order, you represent and warrant that you are a qualified professional or researcher of legal age in your jurisdiction; that you will use these products solely for in vitro laboratory research; that you will not administer, ingest, inject, or otherwise consume any product purchased; and that you will handle, store, and dispose of all materials in accordance with all applicable federal, state, and local laws and regulations.
Max Nutrition USA does not provide dosing, administration, protocol, or medical advice through any channel, including direct messages, email, or phone. Any informal use-related questions will be declined.
Max Nutrition USA assumes no liability for misuse, improper handling, or use outside of a controlled research setting. The purchaser assumes all risks and responsibilities associated with the use, storage, and handling of these products.